English: Thank you for those questions. As you highlight, and as I said in my statement, there are more than 100,000 people in Wales affected by this group of conditions. On top of that, of course, there are their families and carers; there will be an impact on their lives too. I'll just try and run through your questions. I think with the last point, I certainly tried to answer the point about improving neuro rehab, both in my statement but also in response to Mark Isherwood's list of questions. On the broader point about treatment delays from approval to provision, there is always something about how you plan to have a treatment provided once it's gone through the appraisal process. We're talking here about medicines rather than other forms of treatment. And there's something also here about what we're trying to improve more generally in the way that we manage the system in Wales. It's why I've had very constructive conversations with the Association of the British Pharmaceutical Industry about how this works, and about having an earlier conversation as they have drugs in development and at what point the service will be aware of what they're doing and what is likely to come up. Because part of the challenge in the past about having some of the variants in treatment in medicines being approved to being available has been the ability to plan for that service, to change different parts of the service itself. It wasn't just as simple as dropping in a new medicine onto the scripts available, but actually what you need to plan around that as well. That did account for some of the delays in Sativex being available. And, again, I wrote to Members in March to outline where we were, and I've had follow-up correspondence from the Multiple Sclerosis Society in Wales as well, which has been helpful, I think, to get to a point where we do now have genuine nationwide provision. There are particular challenges about having that whole pathway set up in south Wales that I think have been resolved, and if not the offer has been made for the MS Society to meet with the chair of Cardiff and Vale health board to run through any outstanding issues. I think it's important that we recognise and to have an open door to understand what we can do to improve, but in north Wales there are particular challenges where people are going into the system in north-west England, where some people were not being prescribed Sativex by clinicians based in England, even though it was available for them as patients who were resident in Wales. That highlights the fact that this is an area where we've made more progress than other UK nations. We're still the only UK nation to regularly make Sativex available within the United Kingdom. On your point about the best use of diagnostic equipment, I think we need to think properly about how we plan and deliver the service, because we have the workforce that we have as well as the equipment. And, actually, we'll need a workforce to be able to staff that equipment during use, and I need to be persuaded whether we do need more workforce available at different points in the day, and to make sure that equipment is available 24/7. Some of that depends on whether somebody is having an elective or an emergency admission, but, actually, I think that's a proper case of workforce planning and not just having more equipment. We need to think about how we make best use of our capacity and ability across the system. But there is something there about local healthcare that, again, I think I tried to highlight in answer to other questions about how we equip and support people within our local health service, both to intervene and provide treatment and care when they could and should, as well as to diagnose whether these conditions are there and to understand how that treatment is progressing.
Welsh: Diolch am eich cwestiynau. Rydych yn tynnu sylw at y ffaith, ac fel y dywedais i yn fy natganiad, fod mwy na 100,000 o bobl yng Nghymru yn cael eu heffeithio gan y grŵp hwn o gyflyrau. Ar ben hynny, wrth gwrs, mae eu teuluoedd a'u gofalwyr; bydd yn effeithio ar eu bywydau nhw hefyd. Rhoddaf gynnig ar fynd drwy eich cwestiynau. Rwy'n credu gyda'r pwynt olaf, yn sicr fe wnes i geisio ateb y pwynt ynghylch gwella adferiad niwro, yn fy natganiad a hefyd mewn ymateb i restr cwestiynau Mark Isherwood. Ar y pwynt ehangach am oedi yn y driniaeth rhwng y gymeradwyaeth a'r ddarpariaeth, mae 'na rywbeth bob amser am sut yr ydych chi'n bwriadu darparu triniaeth ar ôl iddi fynd drwy'r broses werthuso. Rydym yn sôn yma am feddyginiaethau yn hytrach na mathau eraill o driniaeth. Ac mae 'na rywbeth hefyd yma am yr hyn yr ydym yn ceisio ei ddiwygio yn fwy cyffredinol yn y ffordd yr ydym yn rheoli'r system yng Nghymru. Dyna pam yr wyf wedi cael sgyrsiau adeiladol iawn â Chymdeithas Diwydiant Fferyllol Prydain ynglŷn â sut y mae hyn yn gweithio, ac am gael sgwrs yn gynharach gan fod ganddyn nhw gyffuriau yn cael eu datblygu, ynghylch pryd fydd y gwasanaeth yn dod yn ymwybodol o'r hyn y maen nhw'n ei wneud a'r hyn sy'n debygol o ddigwydd. Oherwydd rhan o'r her yn y gorffennol ynglŷn â chael cymeradwyaeth i rai o'r amrywiadau mewn triniaeth â meddyginiaethau hyd nes y byddant ar gael, fu'r gallu i gynllunio ar gyfer y gwasanaeth hwnnw, i newid gwahanol rannau o'r gwasanaeth ei hunan. Nid oedd yn fater mor syml â rhoi meddyginiaeth newydd ar y presgripsiynau, ond yn hytrach mae angen i chi gynllunio o'i gwmpas hefyd. Roedd hynny'n esbonio peth o'r oedi cyn bod Sativex ar gael. Ac, eto, ysgrifennais at yr Aelodau ym mis Mawrth yn amlinellu ein sefyllfa, ac rwyf wedi cael gohebiaeth wedyn gan Gymdeithas Sglerosis Ymledol Cymru hefyd, a fu'n ddefnyddiol, rwy'n credu, i gyrraedd y man lle mae gennym bellach ddarpariaeth wirioneddol genedlaethol. Mae yna heriau penodol ynglŷn â sefydlu'r llwybr cyfan hwnnw yn y De, ac rwy'n credu bod yr heriau hynny wedi eu datrys. Ac os na, mae'r cynnig wedi ei wneud i'r Gymdeithas Sglerosis Ymledol gael cwrdd â chadeirydd bwrdd iechyd Caerdydd a'r Fro i redeg trwy unrhyw faterion sy'n weddill. Credaf ei bod yn bwysig inni gydnabod a chadw drws agored i ddeall yr hyn y gallwn ei wneud i wella. Ond yn y Gogledd mae yna heriau penodol lle mae pobl yn mynd i'r system yng ngogledd orllewin Lloegr. Nid oedd rhai pobl yn cael presgripsiwn am Sativex gan glinigwyr yn Lloegr, er ei fod ar gael iddyn nhw fel cleifion a oedd yn preswylio yng Nghymru. Mae hynny'n tynnu sylw at y ffaith bod hwn yn faes yr ydym ni wedi gwneud mwy o gynnydd ynddo na gwledydd eraill y DU. Y ni yw'r unig wlad yn y DU o hyd sydd wedi sicrhau bod Sativex ar gael yn rheolaidd o fewn y Deyrnas Unedig. Ar eich pwynt ynglŷn â'r defnydd gorau o offer diagnostig, credaf fod angen inni feddwl yn iawn am y ffordd yr ydym yn cynllunio a chyflwyno'r gwasanaeth, oherwydd mae gennym y gweithlu yn ogystal â'r offer. Ac, mewn gwirionedd, bydd angen gweithlu sy'n gallu staffio'r offer hwnnw pan ddefnyddir ef, ac mae angen i mi gael fy argyhoeddi bod angen mwy o weithlu arnom ar wahanol adegau o'r diwrnod, a sicrhau bod yr offer ar gael drwy'r dydd a'r nos, gydol yr wythnos. Mae rhywfaint o hynny'n dibynnu ar a gafodd y claf dderbyniad dewisol neu dderbyniad argyfwng, ond, mewn gwirionedd, rwyf i o'r farn fod hynny'n fater o gynllunio'r gweithlu'n gywir ac nid yn fater o fod â mwy o offer yn ein meddiant. Mae angen inni feddwl am y ffordd y gallwn wneud y defnydd gorau o'n capasiti a'n gallu ar draws y system. Ond mae yna rywbeth yno am ofal iechyd lleol yr wyf i, eto, yn credu fy mod wedi ceisio tynnu sylw ato wrth ateb cwestiynau eraill ynghylch sut yr ydym yn darparu a chefnogi pobl yn ein gwasanaeth iechyd lleol, sef ymyrryd a rhoi triniaeth a gofal pryd y gallen nhw ac y dylen nhw, yn ogystal â chanfod a yw'r cyflyrau hyn yn bresennol a deall sut mae'r driniaeth honno'n dod yn ei blaen.